Related Experiment Video
Updated: Aug 16, 2025

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
Published on: May 13, 2016
The roles of ETS transcription factors in liver fibrosis
Li-Ye Zhang1,2,3, Yong Tan1,2,3, Xiao-Jie Luo1,2,3
1Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.
Abstract:
E26 transformation specific or E twenty-six (ETS) protein family consists of 28 transcription factors, five of which, named ETS1/2, PU.1, ERG and EHF, are known to involve in the development of liver fibrosis, and are expected to become diagnostic markers or therapeutic targets of liver fibrosis. In recent years, some small molecule inhibitors of ETS protein family have been discovered, which might open up a new path for the liver fibrosis therapy targeting ETS. This article reviews the research progress of ETS family members in the development liver fibrosis as well as their prospect of clinical application.
Insights
The E26 transformation specific (ETS) protein family, particularly ETS1/2, PU.1, ERG, and EHF, are implicated in liver fibrosis. Small molecule inhibitors targeting ETS proteins offer a promising new therapeutic strategy for liver fibrosis.
Area of Science:
- Molecular Biology
- Hepatology
- Oncology
Background:
- The E26 transformation specific (ETS) protein family comprises 28 transcription factors.
- Five ETS members (ETS1/2, PU.1, ERG, EHF) are linked to liver fibrosis development.
- ETS proteins are potential diagnostic markers and therapeutic targets for liver fibrosis.
Purpose of the Study:
- To review research on ETS family members in liver fibrosis.
- To explore the clinical application prospects of targeting ETS in liver fibrosis therapy.
Main Methods:
- Literature review of scientific articles and research progress.
- Analysis of the role of specific ETS proteins in liver fibrosis.
- Investigation of small molecule inhibitors targeting the ETS protein family.
Main Results:
- ETS1/2, PU.1, ERG, and EHF are identified as key players in liver fibrosis.
- Small molecule inhibitors targeting ETS proteins have been developed.
- These inhibitors represent a novel therapeutic avenue for liver fibrosis.
Conclusions:
- ETS proteins are crucial in liver fibrosis pathogenesis.
- Targeting ETS proteins with small molecule inhibitors shows therapeutic potential.
- Further research is warranted to translate these findings into clinical applications for liver fibrosis treatment.
More Related Videos
06:463D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis
Published on: February 25, 2022
08:50In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
Related Concept Videos
Cell Specific Gene Expression
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Master Transcription Regulators
General Transcription Factors
Transcription Factors